Barrett's%20esophagus Signs and Symptoms

Signs and Symptoms

Introduction

Defined as the endoscopic finding in the distal esophagus of proximal-appearing columnar-lined esophagus of at least 1-cm length that is confirmed by histology
Considered a premalignant metaplastic condition that usually involves the distal esophagus
- It is postulated that exposure of the esophageal epithelium to acid damages the lining resulting in chronic esophagitis and its healing involves metaplastic process
The incidence of progressing to adenocarcinoma is approximately 0.27-0.59% of Barrett’s esophagus patients per year
- Intestinal metaplasia is not required for diagnosis, though risk of progression to carcinoma is higher in its presence
Diagnosed by endoscopy and histological examination

Risk Factors

Chronic gastroesophageal reflux disease (GERD)
White or Hispanic race
Male
Advancing age (>50 years, reaching a plateau in the 60’s) - reported as a significant risk factor in various Asian studies
Hiatal hernia
Smoking
Central obesity (intra-abdominal body fat distribution)
Alcohol (as shown in an Asian study)

Product Highlight - Salofalk

12 Mar 2021

SALOFALK – Mesalazine 1.5 g PR granules

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).